Visão geral da empresa
A biotechnology firm focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally, Novavax, Inc. primarily commercializes its Nuvaxovid COVID-19 vaccine and the R21 Matrix-M adjuvant malaria vaccine. The company operates within the Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized entity distinct from broader pharmaceutical conglomerates. With a market capitalization of $1.30B, annual revenue of $1.12B, and an employee count of 749, the firm maintains a specific scale that reflects its status as a mid-sized player in the global immunization landscape. These valuation and revenue figures indicate that while the company possesses significant operational capacity, its market size suggests it is not yet a dominant market leader comparable to the largest pharmaceutical giants, yet it commands substantial capital attention relative to its revenue base.
Saúde financeira
Novavax reported a trailing twelve-month revenue of $1.12B and a net income of $440.30M, resulting in an EBITDA of $590.85M. The significant gap between the $1.12B revenue and the $440.30M net income, while the EBITDA remains higher at $590.85M, reveals a substantial cost structure where non-operating expenses or specific tax considerations impact the bottom line more aggressively than the core operating earnings. The company's free cash flow stands at -$331,942,880, indicating a current consumption of cash that limits immediate financial flexibility and suggests a reliance on existing cash reserves or external financing to fund operations and growth initiatives. Regarding profitability efficiency, the gross margin is 63.5%, the operating margin is 14.2%, and the profit margin is 39.2%, where the high profit margin relative to the operating margin highlights the impact of non-operating items or specific accounting adjustments on the final profitability picture. The balance sheet shows $735.08M in cash against $278.05M in debt, with a debt-to-equity ratio listed as N/A, suggesting a conservative liquidity stance despite the cash burn rate. Liquidity is further supported by a current ratio of 2.13, which indicates a robust ability to meet short-term obligations with its short-term assets. Return on Equity is N/A, while the Return on Assets is 25.7%, a metric that reveals highly effective management in utilizing its asset base to generate returns, even in the context of a negative equity position or specific capitalization structure.
Avaliação de valorização
The trailing P/E ratio (TTM) is 3.09, whereas the forward P/E is -10.33, implying that the market expects the company to be unprofitable in the upcoming period or that current earnings are being driven by non-recurring items that are not expected to persist. The price-to-book ratio stands at -10.15, which indicates a market valuation significantly below the book value, often reflecting investor concerns regarding the quality of assets or the risk profile of the biotechnology business model. Alternative valuation metrics such as the price-to-sales ratio of 1.16 and an EV/EBITDA of 1.43 suggest that the stock is priced very cheaply relative to its sales and earnings power, potentially offering value if the company can stabilize its earnings trajectory. The 52-week high is $11.97 and the 52-week low is $5.01, providing a range within which the stock has traded, though the specific current price position relative to this range requires real-time calculation not provided in the static data. The beta value is 2.65, which means the stock exhibits high volatility relative to the broader market, moving approximately 2.65 times as much as the market index in either direction.
Growth & Income
Novavax reported a revenue growth year-over-year of 66.6%, while the earnings growth year-over-year is N/A, indicating that earnings are not currently tracked or are negative, which implies that top-line expansion is outpacing bottom-line profitability or that earnings are not yet a reliable growth metric in the current fiscal cycle. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings and cash flow back into research, development, and commercialization efforts rather than distributing income to shareholders. This lack of dividend distribution aligns with the company's life-stage profile where capital retention is prioritized for vaccine development and market expansion. Overall, the growth and income profile is characterized by rapid revenue expansion without current earnings growth or dividend income, relying entirely on operational scaling and future product launches to drive shareholder value.